DYNATRONICS CORP

DYNTQ
Country: United StatesPrice: $0.00Market Cap: $1,604

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

3 / 13

NEUTRAL / FAIL

Median fair value

$0.14

+139900.0% vs price

Models with upside

2 / 17

Positive margin of safety

Strongest signal

DYNTQ undervalued: all 2 models price fair value above $0.00 (median $0.14)

Key risk

All 8 investors flag DYNTQ's growth

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILNEUTRALFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/A+99.9%N/AN/AN/A+99.9%N/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2026-01-01–2026-11-01

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2026-01-01–2026-11-01

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2026-01-01–2026-11-01

Latest source filing: 2025-10-14

Score computed: 2026-11-14

Where It Passes

  • Valuation models100% pass✓ 2▾

    DYNTQ undervalued: all 2 models price fair value above $0.00 (median $0.14)

    Munger fair value$0.14
    ✓Munger+99.9% margin vs $0.00
    Ackman fair value$0.14
    ✓Ackman+99.9% margin vs $0.00
  • Cash Flow70% pass✓ 9✗ 3▾

    7 of 10 pass — Buffett, Lynch and Sleep object

    Free Cash Flow Proxy$-10.4M
    ✗BuffettPositive and growing
    FCF Positive and Growing$0.3M
    ✗LynchPositive and growing
    Operating Cash Flow$0.3M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=1.95%, ROA=-70.61%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)0.0x
    ✓Dreman< 8x
    P/E or FCF YieldFCF Yield=16841.3%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive10/16 years FCF positive
    ✓MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap16882.0%
    ✓Ackman>= 4%
    Price / FCF per Share0.0x
    ✓Ackman<= 25
    Positive Operating Cash Flow frequency11/16 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$0.3M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+16841.33%; #6/4519 (top 0.1%)
    ✓OshaughnessyTop 10% of eligible cross-section

Where It Falls Short

  • Growth0% pass✗ 13▾

    All 8 investors flag DYNTQ's growth

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 0.0% vs Rev: 0.0%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency2/16 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-15.8%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 23.5% -> 21.9%, operating margin -7.0% -> -9.0%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR-10.5%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Efficiency0% pass✗ 11▾

    All 8 investors flag DYNTQ's efficiency

    Current Ratio1.09
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)-19.3%
    ✗Buffett> 10%
    ROIC - WACC-29.3%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-128.7%
    ✗Greenblatt> 25%
    Current Ratio Change YoY1.09 -> 1.09
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY1.77x -> 1.77x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities1.09
    ✗Dreman> 1.5
    Return on Invested Capital
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-10.1%; FY2024: ROIC=-30.4%; FY2025: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/4 years above 12% (latest -30.4%)
    ✗SleepROIC > 12% in a majority of years
  • Verdicts0% pass✗ 13▾

    Split decision: 13 FAIL · 3 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (1/9)✗BuffettFAIL (0/9)✗LynchFAIL (0/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (2/11)✗MungerFAIL (0/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)✗AckmanFAIL (3/9)✗TempletonFAIL (2/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Profitability6% pass✓ 3✗ 32▾

    15 of 16 flag DYNTQ's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)2/16 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)2/16 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-147.1%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-9.0% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-10.4M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-334.2%
    ✗Lynch> 15%
    EBIT / Enterprise ValueN/A (EV <= 0)
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-128.7%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-70.61%
    ✗PiotroskiROA > 0
    ROA Change YoY-70.61% -> -70.61% (delta: +0.00%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=1.95%, ROA=-70.61%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY21.9% -> 21.9%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue-39.8%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-334.2%
    ✗Dreman> 12%
    Margin of SafetyP/B=0.0x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-229.1% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency2/16 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-9.0%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-334.2%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-7.0% (2023) -> -9.0% (2025)
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 23.5% -> 21.9%, operating margin -7.0% -> -9.0%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-679651.43%; #6313/6340 (top 99.6%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+38.93%; #990/3702 (top 26.7%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity-334.18%; #5008/5226 (top 95.8%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.2843; #4564/5884 (top 77.6%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Debt & Leverage8% pass✓ 1✗ 14▾

    11 of 12 flag DYNTQ's debt & leverage — Graham, Buffett, Lynch +8 more

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest Coverage
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity
    ✗Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities1.09
    ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity
    ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
    Debt Levels
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-6.0x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity
    ✗Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)
    ✗AsnessTop 30% of eligible cross-section
  • Valuation15% pass✓ 12✗ 16▾

    11 of 13 flag DYNTQ's valuation — Graham, Lynch, Greenblatt +8 more

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio0.0x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise ValueN/A (EV <= 0)
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-128.7%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)0.0x
    ✓Dreman< 8x
    Price / Book Value per Share0.0x
    ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-652761.3%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=16841.3%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=0.0x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share0.0x
    ✓Ackman<= 25
    Price vs. Trailing Low10000% of trailing low ($0.00)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-679651.43%; #6313/6340 (top 99.6%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+2033.7930; #20/6449 (top 0.3%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share0.00x
    ✓SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-86.1%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+17078.0318; #18/5247 (top 0.3%)
    ✓OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+16841.33%; #6/4519 (top 0.1%)
    ✓OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+0.00%; #2690/6202 (top 43.4%)
    ✗OshaughnessyTop 10% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Medical Equipment
SIC Sector: Measuring & Medical Instruments
Size: Micro Cap($1,604)
Revenue: $27.4M+0.0% YoY
Net Income: $10.9M+0.0% YoY

Financial Snapshot

Operating Margin-9.0%
Return on Equity-334.2%
Debt / Equity--
Current Ratio1.09
EPS (Diluted)$-1.43
Shares Retired−50.7%

Similar Companies

ALCALCON INC
$35.6B
PHGKONINKLIJKE PHILIPS NV
$29.7B
WSTWEST PHARMACEUTICAL SERVICES INC
$29.0B
SNNSMITH & NEPHEW PLC
$13.1B

Shareholder Return

Fiscal 2025

Issued 50.7% of shares last year.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2025-09-30

2024-10-01 – 2025-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense.

Q1 FY 2026

2025-07-01 – 2025-09-30

Sources
FY 2025
Sources
  • 10-K · 2025-10-14
FY 2024
Sources
  • 10-K · 2025-10-14
FY 2023
Sources
  • 10-K · 2024-09-24
FY 2022
Sources
  • 10-K · 2023-09-28
FY 2021
Sources
  • 10-K · 2022-09-22
Market Cap$1.6Kcurrent--$176.0Kest.$116.8Kest.------
Revenue$26.8M$7.0M↓8%$27.4M$27.4M↓16%$32.5M↓20%$40.6M↓8%$44.3M
Operating Income-$2.3M-$88.5K↑65%-$2.5M-$2.5M↓8%-$2.3M↑53%-$4.9M↓2%-$4.8M
Net Income-$10.7M-$201.9K↑45%-$10.9M-$10.9M↓304%-$2.7M↑46%-$5.0M↓25%-$4.0M
EPS (Diluted)--$-0.03↑67%$-1.43$-1.43↓43%$-1.00↑32%$-1.46↓11%$-1.32
Gross Margin21.5%24.7%↓5%21.9%21.9%↓6%23.5%↓6%25.0%↑4%24.1%
Operating Margin-8.5%-1.3%↑62%-9.0%-9.0%↓28%-7.0%↑42%-11.9%↓11%-10.7%
ROE-350.8%—-334.2%-334.2%↓1654%-19.1%↑35%-29.5%↓60%-18.4%
Total Debt$3.6M$3.6M↑12%--$3.1M↓13%$3.6M↑105%$1.7M↑32199%$5.4K
Shareholders' Equity$3.1M$3.1M↓78%$3.3M$3.3M↓77%$14.2M↓16%$16.9M↓22%$21.7M
Current Ratio1.071.07↓21%1.091.09↓21%1.37↓12%1.56↓19%1.94
Debt / Equity1.191.19↑404%—0.95↑280%0.25↑144%0.10↑41477%0.00
Operating Cash Flow$106.6K-$93.3K↓193%$300.6K$300.6K↑119%-$1.6M↓534%$371.1K↑108%-$4.9M
Free Cash Flow$75.9K-$93.6K↓193%$270.1K$270.1K↑115%-$1.9M↓1106%$184.3K↑104%-$5.2M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Medical Equipment

DYNTQ vs Peers — Financial Grading

Revenue$27.4MBottom 25%
Net Income$10.9MBottom 25%
ROE-334.2%Bottom 25%
D/E—
Op. Margin-9.0%Bottom 25%
Curr. Ratio1.09Bottom 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11